Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSCAR: Denosumab or Zoledronic Acid for Bone Metastases in mRCC
NCT03408652Phase 3Terminated
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab, zoledronic acid in metastatic renal cell carcinoma (mRCC), bone metastases, sponsored by Centre Léon Bérard. Started Mar 2019; status: terminated.
02
Drugs
denosumabzoledronic acid
03
Conditions
metastatic renal cell carcinoma (mRCC)bone metastases
Beyond the preview
Go deeper on NCT03408652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408652.